The latest Novartis action to shutdown RNAi research based on:
"... the lingering problems associated with delivering these therapies tied to the small number of relevant targets they could shoot for drove the move."
http://www.fiercebiotech.com/story/breaking-novartis-slams-brakes-rnai-development-efforts/2014-04-14
This contrasts with the EET and potential Phenomica progress in which:
- The delivery problem has been completely resolved;
- The targeting problem looks like it can be feasibly addressed; and
- The complex RNA payload against gene expression can be replaced with a simple payload against phenotype expression.
Compare the multiple billion$ directed to RNAi programmes - where Phylogica's tens of million$ actually has produced a significantly more effective platform.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
0.000(0.00%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11 | $1.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 420 | 1 |
View Market Depth
| Last trade - 07.03am 16/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |
Day chart unavailable